Efficacy of selective laser trabeculoplasty following incisional glaucoma surgery

Robert Allan Sharpe¹, Leah L Kammerdiener², David B. Williams³, Sudeep K. Das¹, Matthew J. Nutaitis⁴

¹Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina 29425, USA
²Jacksonville Naval Hospital, Jacksonville, Florida 32214, USA

Correspondence to: Robert Allan Sharpe. Medical University of South Carolina, Storm Eye Institute, 167 Ashley Avenue, Charleston, South Carolina 29425, USA. sharpera@musc.edu

INTRODUCTION

Glaucoma is the leading cause of irreversible blindness affecting more than 70 million individuals worldwide[1]. The current mainstay of treatment involves lowering the intraocular pressure (IOP) to slow or halt progression of optic nerve damage and subsequent vision loss[1-2]. First-line treatment has historically included topical ocular antihypertensive medications with escalation to oral medications, laser, or incisional surgery if conservative measures fail.

Selective laser trabeculoplasty (SLT) was first developed in dermatology for selective photothermolysis to pigmented cellular structures[3]. SLT was then introduced as a non-invasive treatment option for glaucoma in 1995 and ultimately approved by the Food and Drug Administration in 2001[4-5]. SLT uses a Q-switched, frequency-doubled, 532 nm, neodymium-doped yttrium aluminum garnet (Nd:YAG) laser that selectively targets pigmented trabecular meshwork cells without causing collateral damage to adjacent structures[4,6]. Although the mechanism by which laser trabeculoplasty reduces IOP remains uncertain, it appears to involve 3 mechanisms: mechanical distension of Schlemm’s canal, dislodging of trabecular cells, and stimulation of cellular production and turnover of extracellular matrix[7]. Argon laser trabeculoplasty (ALT) is a similar treatment modality that predates SLT, and while a recent systematic review revealed similar IOP reductions following both lasers, histologic and ultrastructural studies have shown that, unlike ALT, SLT produces less extensive damage and no coagulative effects on the trabecular meshwork (TM)[5-6,8-9]. Therefore, SLT is theoretically safer and more repeatable.

When IOP remains uncontrolled despite maximal medical therapy, surgery is required to further reduce IOP. Trabeculectomy remains the most commonly performed glaucoma surgery and produces significant IOP reductions[1,10]. In conjunction with trabeculectomy, the ExPress mini shunt...

Abstract

AIM: To evaluate the efficacy of selective laser trabeculoplasty (SLT) in glaucomatous eyes with previous incisional glaucoma surgery.

METHODS: A retrospective cohort of eyes that underwent SLT at a single institution from 2013-2015 were followed for 1y. Reduction in intraocular pressure (IOP) following SLT was evaluated in eyes with prior trabeculectomy with ExPress mini shunt (Alcon, Ft Worth, TX, USA), Ahmed valve (New World Medical, Cucamonga, CA, USA), or combined phacoemulsification-trabeculectomy. A control group was included with eyes without prior surgery that underwent SLT. Success was defined as >20% drop in IOP from pre-SLT baseline.

RESULTS: One-hundred and six eyes were included with 53 in both the prior glaucoma surgery (PGS) and no prior glaucoma surgery (NPGS) groups. Mean pre-SLT IOP was 19.2±4.3 and 20.6±6.0 mm Hg for PGS and NPGS groups, respectively (P=0.17). Both groups produced statistically significant IOP reductions at 1 and 6mo (P<0.04). At 6mo, mean IOP reduction reached 7.3% and 10.8% for the PGS and NPGS groups, respectively (P=0.42). Overall, 27.9% and 31.7% of eyes in PGS and NPGS groups met success criteria at 1y (P=0.70). In the PGS group, eyes with baseline IOP ≥21 mm Hg had IOP reductions of 18.1% (P<0.001), 16.7% (P=0.01), and 8.4% (P=0.31) compared to eyes with baseline IOP <21 mm Hg who had IOP reductions of 2.3% (P=0.39), 3.4% (P=0.19), and 1.1% (P=0.72) at 1, 6mo, and 1y, respectively.

CONCLUSION: SLT is efficacious in eyes with prior incisional glaucoma surgery and results in similar IOP reductions compared to eyes without PGS. A larger IOP reduction is observed following SLT in eyes with higher pre-SLT IOP.

KEYWORDS: glaucoma; selective laser trabeculoplasty; trabeculectomy; Ahmed glaucoma valve; intraocular pressure

DOI:10.18240/ijo.2018.01.13

Citation: Sharpe RA, Kammerdiener LL, Williams DB, Das SK, Nutaitis MJ. Efficacy of selective laser trabeculoplasty following incisional glaucoma surgery. Int J Ophthalmol 2018;11(1):71-76
Selective laser trabeculoplasty after glaucoma surgery

(Alcon, Ft Worth, TX, USA), a non-valved stainless steel implant which drains aqueous into the intrascleral space, is often used in an attempt to minimize complications of trabeculectomy[10]. Glaucoma drainage devices, such as the Ahmed valve (New World Medical, Cucamonga, CA, USA) have gained in popularity as an alternative to trabeculectomy and have been shown to result in comparable IOP reductions with fewer hypotony complications[12-14]. Phacoemulsification-trabeculectomy is a useful option for a patient to simultaneously address cataract and glaucoma[15-18].

Prior studies have shown SLT to produce approximately a 20%-30% reduction in IOP in eyes without prior glaucoma surgery (PGS) [19-21]. To date, only one other study has investigated the utility of SLT in eyes that have previously undergone incisional glaucoma surgery [22]. Zhang et al [22] conducted a prospective study of 18 eyes whose IOP remained uncontrolled following trabeculectomy. These eyes then underwent SLT and experienced an average of 24% in IOP reduction after 9mo. The purpose of the current study is to further explore SLT as a treatment option in eyes with previous incisional glaucoma surgery whose IOP remains or becomes uncontrolled.

SUBJECTS AND METHODS

A retrospective, electronic medical record review of patients at the Medical University of South Carolina (MUSC) was conducted following study approval by the MUSC Institutional Review Board. The study adhered to the principles described in the Declaration of Helsinki. Patients were identified by reviewing scheduling logs for glaucoma laser clinic days over a 3-year period from 2013 to 2015. Clinical data were then gathered beginning at the initial SLT and followed for 1y. At each time point, the difference in mean IOP for each group was not statistically significant between the PGS and NPGS groups. Mean IOP pre-SLT was 19.2±4.3 mm Hg and 20.6±6.0 mm Hg for PGS and NPGS groups, respectively (P

RESULTS

A total of 106 eyes met inclusion criteria with 53 in each group. Demographics are summarized in Table 1. Mean age was higher in the PGS group at 71.8±8.6 vs 67.7±10.5y in NPGS group (P=0.03). Other baseline characteristics including sex, race, and type of glaucoma were evenly matched among groups. Mean IOP pre-SLT was 19.2±4.3 mm Hg and 20.6±6.0 mm Hg for PGS and NPGS groups, respectively (P=0.17).

At each time point, the difference in mean IOP for each group was not statistically significant between the PGS and NPGS groups over 1y (P>0.17). The overall mean IOP at pre-SLT, 1, 6mo, and 1y is shown in Figure 1.

For IOP reduction from baseline, the PGS and NPGS groups had a 7.11% and 4.56% decrease at 1mo and a 7.3% and 10.8% decrease at 6mo (P<0.05), respectively, as shown in
Figure 2. At 1y, PGS group maintained a 3.51% reduction while the NPGS group showed a 0.66% increase in mean IOP, but neither reached statistical significance ($P>0.32$). Between groups, there was no statistically significant difference in IOP reductions from baseline at any time over 1y ($P=0.63$).

Success in this study was defined as an IOP reduction of >20%. At 1mo, 28.3% and 24.5% of eyes in the PGS and NPGS groups, respectively, met this criterion for success (Figure 3). At 1y, 27.9% and 31.7% of eyes in the PGS and NPGS groups met this benchmark. There was no statistically significant difference between the groups for percentage of successful treatments at any time point ($P>0.66$).

The mean number of medications pre-SLT was 2.5±1.6 and 2.0±1.5 for the PGS and NPGS groups, respectively ($P=0.09$).

Both groups were on a higher number of medications at 1y averaging 2.9±1.4 and 2.2±1.4 for PGS and NPGS groups, respectively; however, the difference for PGS group reached statistical significance ($P<0.01$) while the difference for the NPGS group did not ($P=0.13$).

The PGS group was subdivided into eyes with initial IOP of ≥21 mm Hg ($n=16$) or <21 mm Hg ($n=37$). The mean pre-SLT IOP was 24.2±3.2 and 17.1±2.6 mm Hg for the higher and lower initial IOP groups, respectively ($P<0.01$). The IOP trend over 1y for 2 groups based on pre-SLT IOP is shown in Figure 4. At 1, 6mo, and 1y, the group with ≥21 mm Hg pre-SLT IOP exhibited mean reductions in IOP of 18.1%, 16.7%, and 8.4%, respectively ($P<0.001$, $P<0.01$, $P=0.31$) as shown in Figure 5. At each of these time points, the mean percent IOP reduction was greater for the group with higher pre-SLT IOP, and this difference reached statistical significance at 1 and 6mo ($P≤0.05$). Furthermore, the group with initial IOP of <21 mm Hg did not exhibit significant IOP reductions at any time point. This group showed a mean IOP reduction of 2.3%, 3.4%, 1.1% at 1, 6mo, and 1y, respectively ($P=0.39$, $P=0.19$, and $P=0.72$).

Figure 2. Mean percentage reduction in IOP for PGS and NPGS groups

Figure 3. Percentage of eyes in PGS and NPGS groups meeting criteria for successful treatment of a >20 mm Hg decrease in pre-SLT IOP.
racial differences, a larger mean percent IOP reduction was observed in non-Hispanic white patients compared to black patients by 15.9% ($P=0.01$; Figure 6). Although the mean pre-SLT IOP was higher in whites than blacks at 20.4±4.3 vs 18.8±4.1 mm Hg, respectively, the difference was not statistically significant ($P=0.19$). Also, the differences in mean IOP at 1, 6mo, and 1y did not exhibit statistically significant differences between white and black patients, nor did the difference in mean percent IOP reduction observed at 1mo persist at 6mo or 1y between these groups. Since there was only 1 Asian patient, no correlations based on this race were able to be explored.

**DISCUSSION**

In advanced glaucoma, incisional surgery is often required to control IOP by bypassing the TM with shunting and filtering procedures. SLT, on the other hand, reduces IOP by improving the function of the TM and is commonly employed in earlier stages of glaucoma before significant TM derangements set in. Current practice patterns suggest that if a patient required incisional surgery, the TM was deemed largely non-functional and therefore had to be bypassed. Therefore, SLT is not commonly employed following incisional glaucoma surgery as it would be assumed to have minimal effect. However, although the TM outflow system may be dysfunctional in eyes with severe enough glaucoma to require surgery, there appears to be a significant residual level of activity. This notion is supported by the 25%-30% of patients who underwent SLT at some point after their incisional glaucoma surgeries and exhibited at least a 20% reduction in IOP. The IOP reduction following SLT suggests some level of residual function in the TM pathway that still has potential to be modulated in a postsurgical eye.

It is particularly important to look at the decrease in IOP in the PGS group with a baseline IOP ≥21 mm Hg. At this institution, it is common to offer SLT treatment to patients on maximum tolerated medical therapy with IOP above target. Laser treatment is also commonly offered to patients who would be at target IOP on medications but have intermittent compliance or particularly poor tolerance to their medications. The primary benefit in these patients is to decrease their reliance on drops or delay starting additional drops. When the PGS group is subdivided based on initial IOP, the group with initial IOP <21 mm Hg had a significantly smaller reduction in IOP at follow up. This group subsequently skewed the overall mean IOP lowering effect toward lower mean IOP reductions.

Prior SLT studies have historically had a mean baseline IOP ranging from 23.8 to 29.3 mm Hg, which more closely approximates the initial IOP of the PGS subgroup with higher baseline ≥21 mm Hg, which was 24.2±3.2 mm Hg in this study. This cohort, therefore, is more likely to represent the group of patients who have had prior incisional glaucoma surgery but need further IOP reduction in addition to medications versus an alternative to replacing medications. This group experienced a 16.7% reduction in IOP at 6mo, which approximates published results in eyes without prior incisional glaucoma surgery. This effect, however, did seem to dissipate by 1y when only an 8.4% IOP reduction from baseline was observed.
Both PGS and NPGS groups were on a higher number of mean medications at 1y compared to pre-SLT. Although this difference was statistically significant in the PGS group, the actual difference was only an average of 0.4 additional drops. This finding suggests that by 1y, there was a trend to be on more medications, which coincides with the observed tapering of IOP lowering effect from the SLT. However, an additional benefit of SLT in these patients is a decrease in diurnal IOP fluctuation\cite{21}. IOP fluctuation has been shown to be an independent risk factor for progression of glaucoma, and although medications can reduce IOP fluctuation, compliance issues may limit their efficacy\cite{21,28}.

An important observation is that none of these patients required incisional surgery during that first year and that successful IOP lowering was obtained with SLT and medications changes. This finding is clinically important, especially in areas where subspecialty glaucoma care can be difficult to obtain. In current ophthalmology practice, patients who have required incisional glaucoma surgery are often referred to glaucoma subspecialists when their IOP starts to trend upwards again in anticipation of additional incisional surgery. However, SLT is a procedure commonly performed by comprehensive ophthalmologists, and this study supports a trial of SLT in patients with prior incisional glaucoma surgery who may have otherwise been referred to a subspecialist for additional incisional surgery. The major limitation of the study is its retrospective nature. As described above, there may have been different goals for performing the SLT depending on a patient’s initial IOP. Some patients were on maximal tolerated therapy and needed adjunctive treatment while others were primarily treated with SLT to replace medications. A prospective study would be advantageous to better control for this potential selection bias. While further investigation regarding the efficacy of SLT following prior incisional glaucoma surgery is warranted, this study is consistent with Zhang et al\cite{22} suggesting that SLT is an effective and safe treatment option to lower IOP to avoid or postpone subsequent incisional glaucoma procedures. SLT is a widely-available treatment modality and could help further lower IOP in patients who otherwise would face the burden and potential complications of additional incisional glaucoma surgery.

In conclusion, SLT may be efficacious in eyes with prior incisional glaucoma surgery and can result in similar IOP reductions compared to eyes without PGS. Therefore, it warrants consideration as treatment modality in eyes requiring further IOP reduction even in setting of prior incisional glaucoma surgery.

ACKNOWLEDGEMENTS

**Authors’ contribution:** Study design: Kammerdiener LL, Sharpe RA, Nutaitis MJ; Data collection and analysis: Kammerdiener LL, Sharpe RA, Williams DB, Das SK; Manuscript preparation: Kammerdiener LL, Sharpe RA, Williams DB, Das SK, Nutaitis MJ.

**Conflicts of Interest:** Sharpe RA, None; Kammerdiener LL, None; Williams DB, None; Das SK, None; Nutaitis MJ. None.

**REFERENCES**

1 Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA* 2014;311(18):1901-1911.


Selective laser trabeculoplasty after glaucoma surgery


